Targeting Epidermal Growth Factor Receptor–Associated Signaling Pathways in Non–Small Cell Lung Cancer Cells: Implication in Radiation Response
暂无分享,去创建一个
So Yeon Kim | J. Kim | Hong-Gyun Wu | I. Kim | I. Kim | Eun Jung Choi | Yungil Ryu
[1] Jinsong Liu,et al. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. , 2008, Cancer research.
[2] Sanjay Goel,et al. Erratum: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. (Cancer Res (2008) 68 (1953-61)) , 2008 .
[3] R. Herbst,et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Shaomeng Wang,et al. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair , 2008, Molecular Cancer Therapeutics.
[5] Sabine Tejpar,et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience , 2008 .
[6] P. Jänne,et al. Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.
[7] B. Hemmings,et al. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. , 2008, Molecular cell.
[8] Sanjay Goel,et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. , 2008, Cancer research.
[9] M. Fukuoka,et al. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status , 2008, British Journal of Cancer.
[10] A. Lièvre,et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. Shokat,et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. , 2007, Cancer research.
[12] Michael Baumann,et al. Stimulated PI3K-AKT Signaling Mediated through Ligand or Radiation-Induced EGFR Depends Indirectly, but not Directly, on Constitutive K-Ras Activity , 2007, Molecular Cancer Research.
[13] J. Engelman,et al. PI3K Charges Ahead , 2007, Science.
[14] David M Sabatini,et al. Defining the role of mTOR in cancer. , 2007, Cancer cell.
[15] P. Jänne,et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Mitsuo Sato,et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. , 2007, Cancer research.
[17] J. Milanowski,et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Hicklin,et al. Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor , 2007, Clinical Cancer Research.
[19] K. Shokat,et al. Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.
[20] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[21] P. Jänne,et al. Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2006, Clinical Cancer Research.
[22] L. Cantley,et al. Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.
[23] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[24] Jin Ho Kim,et al. Histone Deacetylase Inhibitor–Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53 , 2006, Clinical Cancer Research.
[25] M. Birnbaum,et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. , 2005, Cancer research.
[26] M. Baumann,et al. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[27] T. K. Johnson,et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] G. Scagliotti,et al. The Biology of Epidermal Growth Factor Receptor in Lung Cancer , 2004, Clinical Cancer Research.
[29] A. Kimchi,et al. Autophagy as a cell death and tumor suppressor mechanism , 2004, Oncogene.
[30] Roy S Herbst,et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Birnbaum,et al. Isoform-specific Regulation of Insulin-dependent Glucose Uptake by Akt/Protein Kinase B* , 2003, Journal of Biological Chemistry.
[32] Rosemarie Mick,et al. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. , 2003, International journal of radiation oncology, biology, physics.
[33] J. Schlessinger,et al. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[34] J. Schlessinger. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[35] P. Harari,et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. , 1999, Cancer research.
[36] N. Goldstein,et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] C. Sartor,et al. Epidermal growth factor family receptors and inhibitors: radiation response modulators. , 2003, Seminars in radiation oncology.